On July 19, 2021, Houston, Texas-based Saranas announced a $12.8 million Series B investment led by Baird Capital. Austin-based S3 Ventures also joined the funding round. Wilson Sonsini Goodrich & Rosati represented Saranas in the transaction.

Saranas is a privately held medical device company focusing on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company’s patented Early Bird® Bleed Monitoring System (Early Bird) for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeds immediately before they become complications, improving patient outcomes and lowering healthcare costs. The Early Bird remains the first and only device of its kind.

The company will use the capital to expand its clinical evidence through prospective clinical trials and launch of next generation products, including Bird on a Wire, to address a much broader range of endovascular procedures.

The Wilson Sonsini team that advised Saranas on the transaction includes Elton Satusky, RJ Lang, and Kathy Jordan.

For more information, please see the press release. Further coverage can be found at Houston Business Journal.